Loading…
Black Diamond Therapeutics, Inc. is projected to rise to $1.84 by 2027, a +9% move from its current price of $1.69. BDTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.63 | $1.69 | $1.75 | +0.03% |
| Aug 6 | $1.61 | $1.69 | $1.77 | +0.06% |
| Aug 7 | $1.60 | $1.69 | $1.79 | +0.08% |
| Aug 8 | $1.58 | $1.69 | $1.81 | +0.11% |
| Aug 9 | $1.57 | $1.69 | $1.83 | +0.14% |
| Aug 10 | $1.56 | $1.69 | $1.84 | +0.17% |
| Aug 11 | $1.55 | $1.69 | $1.85 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.55 | $1.69 | $1.85 | +0.19% |
| Week 2 | $1.49 | $1.70 | $1.93 | +0.39% |
| Week 3 | $1.46 | $1.70 | $1.98 | +0.58% |
| Week 4 | $1.42 | $1.70 | $2.04 | +0.77% |
| Week 5 | $1.40 | $1.71 | $2.08 | +0.97% |
| Week 6 | $1.37 | $1.71 | $2.13 | +1.16% |
| Week 7 | $1.35 | $1.71 | $2.17 | +1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Its lead candidate silevertinib is a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, in Phase 2 clinical trial for the treatment of EGFR mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
BDTX is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
BDTX is trading at $1.66 per share with a market cap of $95.12M, and it holds a rank of 4203 by market capitalization. The near-term technical posture is bearish, reflecting a cautious price setup.
A major floor 21.7% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 23.1% above — a clean break opens room to run.
A major ceiling 113.0% above — clearing it would confirm fresh momentum.
Key BDTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.71 | Sell | $1.72 | Sell |
| MA 10 | $1.77 | Sell | $1.75 | Sell |
| MA 20 | $1.83 | Sell | $1.80 | Sell |
| MA 50 | $1.95 | Sell | $1.97 | Sell |
| MA 100 | $2.26 | Sell | $2.18 | Sell |
| MA 200 | $2.64 | Sell | $2.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.13 | Neutral |
| Stoch RSI (14) | 28.05 | Neutral |
| CCI (20) | -122.92 | Sell |
| Williams %R (14) | -85.71 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -6.63 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 14.29 | Buy |
| TRIX (15) | -0.43 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 32.86 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 1.67 | Buy |
| ADX (14) | 15.82 | Neutral |
| ATR (14) | 0.06 | Info |
The stock’s 30-day technical picture shows bearish sentiment with RSI14 at 40. The 50-day simple moving average (SMA50) is $1.99 and the 200-day simple moving average (SMA200) is $2.66.
Support is at $1.61 and resistance at $2.08, with a 30-day price range of $1.32 to $2.09. Annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.61 | $1.69 | $2.38 | 0% | Neutral | |
| $1.43 | $1.84 | $2.51 | +9% | Neutral | |
| $1.42 | $1.89 | $2.70 | +12% | Neutral | |
| $1.45 | $1.98 | $2.92 | +17% | Neutral | |
| $1.47 | $2.06 | $3.14 | +22% | Bullish | |
| $1.94 | $2.80 | $4.37 | +66% | Bullish | |
| $2.08 | $3.07 | $4.90 | +82% | Bullish | |
| $1.95 | $2.93 | $4.78 | +73% | Bullish | |
| $2.04 | $3.14 | $5.21 | +86% | Bullish | |
| $2.02 | $3.17 | $5.35 | +88% | Bullish | |
| $2.69 | $4.61 | $8.37 | +173% | Bullish | |
| $5.25 | $10.56 | $21.25 | +525% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.61 | $1.69 | $2.12 | +0.00% |
| September 2026 | $1.48 | $1.76 | $2.17 | +4.41% |
| October 2026 | $1.44 | $1.73 | $2.16 | -1.79% |
| November 2026 | $1.48 | $1.79 | $2.25 | +3.18% |
| December 2026 | $1.54 | $1.87 | $2.38 | +4.81% |
Click any year to see its month-by-month BDTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BDTX to range from $1.61 to $2.38 through 2026. The $1.69 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BDTX price prediction for 2027 points to an average of $1.84 (low $1.43, high $2.51) — a potential gain of +9% on today's $1.69. Price action looks broadly range-bound.
In 2028, BDTX is projected to trade between $1.42 and $2.70, averaging $1.89 — a potential gain of +12% from today's $1.69. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
Black Diamond Therapeutics, Inc.'s 2029 outlook centres on $1.98, within a $1.45 to $2.92 range. That is up +5% on the projected 2028 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2030, BDTX could reach as high as $3.14, with a base case around $2.06 and support toward $1.47 — roughly +22% from $1.69. Buyers look set to stay in control over this stretch.
Expect BDTX to range from $1.94 to $4.37 through 2031. The $2.80 average target implies a +66% move from current prices. That is up +36% on the projected 2030 average. Momentum favours further upside here.
The BDTX price prediction for 2032 points to an average of $3.07 (low $2.08, high $4.90) — a potential gain of +82% on today's $1.69. Buyers look set to stay in control over this stretch.
In 2033, BDTX is projected to trade between $1.95 and $4.78, averaging $2.93 — a potential gain of +73% from today's $1.69. That is -4% versus the projected 2032 average. Momentum favours further upside here.
Black Diamond Therapeutics, Inc.'s 2034 outlook centres on $3.14, within a $2.04 to $5.21 range. That is up +7% on the projected 2033 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BDTX could reach as high as $5.35, with a base case around $3.17 and support toward $2.02 — roughly +88% from $1.69. Momentum favours further upside here.
Expect BDTX to range from $2.69 to $8.37 through 2040. The $4.61 average target implies a +173% move from current prices. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BDTX price prediction for 2050 points to an average of $10.56 (low $5.25, high $21.25) — a potential gain of +525% on today's $1.69. Momentum favours further upside here.
Investing $1,000 in BDTX today (≈ 591.715976 BDTX) could be worth
$6,249.28
+$5,249.28 (+525%) by 2050 · US Dollar
Based on the average projected BDTX price of $10.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDTXwould be worth at today's price.
$1,000 invested in BDTX on Jul 31, 2025 (≈ 375.939837 BDTX) would be worth
$635.34
-$364.66 (-36.5%) today · 0.64× · US Dollar
Based on a BDTX entry price of $2.66 vs. today's $1.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.76 | $960.23 | -4.0% |
| 1 month ago | $1.84 | $918.48 | -8.2% |
| 3 months ago | $2.6 | $650 | -35.0% |
| 6 months ago | $2.54 | $665.35 | -33.5% |
| 1 year ago | $2.66 | $635.34 | -36.5% |
| All time (5.0y) ago | $10.07 | $167.83 | -83.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDTX forecast.
Our base-case forecast reaches $3.40 around 2040.
Implied market cap at $3.40: $194.83M
The year-by-year forecast begins with neutral sentiment for 2026, showing a min of $1.61, an avg of $1.66, and a max of $2.36 with ROI 0. For 2027 the min is $1.39, the avg is $1.79, the max is $2.46 and ROI is 7.8, followed by 2028 with min $1.38, avg $1.84, max $2.65 and ROI 10.8, and 2029 with min $1.39, avg $1.91, max $2.85 and ROI 15.3, and 2030 with min $1.39, avg $1.97, max $3.03 and ROI 19.
From 2031 onward the forecast turns bullish, with 2031 min $1.87, avg $2.72, max $4.29 and ROI 63.7; 2032 min $1.99, avg $2.96, max $4.78 and ROI 78.5; 2033 min $1.84, avg $2.80, max $4.62 and ROI 68.8; 2034 min $1.95, avg $3.03, max $5.09 and ROI 82.7; 2035 min $1.90, avg $3.03, max $5.17 and ROI 82.3. The forecast for 2040 shows min $2.52, avg $4.41, max $8.11 with ROI 165.5, and by 2050 it projects min $4.86, avg $10.06, max $20.57 with ROI 505.8.
These figures illustrate a long-run bullish trajectory with substantial upside relative to the current price, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $1.97, with a max of $3.03 and ROI 19.
Near term (2026–2030) sentiment is NEUTRAL with 2026 avg $1.66 and 2030 avg $1.97. The long-run forecast turns bullish from 2031 onward, with 2050 avg $10.06, max $20.57, and ROI 505.8.
Yes. The forecast shows a 2035 max of $5.17 and a 2040 max of $8.11, with higher upside possible by 2050 (max $20.57).
Current price is $1.66 and market cap is $95.12M.
The 30-day range is $1.32 to $2.09.
Black Diamond Therapeutics, Inc. Community Discussion
0Share your Black Diamond Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.